Dr. Karen Abbott’s lab is focused on discovering and developing a human antibody that can target a specific form of N-linked tumor glycan found on glycoproteins abundantly expressed on ovarian cancer, glioblastoma, and lung cancer. This research has the potential to lead to new serum-based diagnostic assays and new therapeutic strategies to target these cancers.
Abbott is funded by an Alliance of Glycobiologists NCI grant that is one of only 10 competitively funded Tumor Glycomics Laboratories working to understand how complex carbohydrates contribute to tumor development and progression.
She is also funded by the NCI Innovative Molecular Analysis Technologies grant that supports the development of novel and transformative technologies to develop new therapeutics and diagnostics for cancer. She has been funded for ovarian cancer research since 2010.
Karen Abbott, Ph.D., is an associate professor in the Department of Translational Medicine. Her lab is located at the Translational Glycobiology Institute at FIU in Academic Health Center 5. In 2005, she was awarded an American Cancer Society Postdoctoral Fellowship where she developed lectin capture methods to analyze glycoproteins from human tissues and plasma using mass spectrometry methods.